GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q2 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $200.6 million versus the consensus estimate of $200.47 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q3 2024 revenue of $193-197 million, versus the consensus of $202.4 million.

GoodRx Holdings, Inc. sees FY2024 revenue of $800-810 million, versus the consensus of $806.4 million.

For earnings history and earnings-related data on GoodRx Holdings, Inc. (GDRX) click here.